Publikace
- Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors2020 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Initial characterization of human DHRS1 (SDR19C1), a member of the short chain dehydrogenase/reductase superfamily2019 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters2019 | Farmaceutická fakulta v Hradci Králové
- Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance2019 | Farmaceutická fakulta v Hradci Králové
- Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C32019 | Farmaceutická fakulta v Hradci Králové
- Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds2019 | Farmaceutická fakulta v Hradci Králové
- Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile2018 | Farmaceutická fakulta v Hradci Králové
- Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment2018 | Farmaceutická fakulta v Hradci Králové
- Design, Synthesis, and Biological Evaluation of Isothiosemicarbazones with Antimycobacterial Activity2017 | Farmaceutická fakulta v Hradci Králové
- Flavones Inhibit the Activity of AKR1B10, a Promising Therapeutic Target for Cancer Treatment2015 | Farmaceutická fakulta v Hradci Králové
Loading network view...